Abstract
Pancreas cancer is the fourth leading cause of cancer death due to the limited treatment success rate. The wide number of signalling pathway aberrations contributing to tumorigenesis, progression and drug resistance, is the main reason for unsuccessful treatments in pancreatic cancer. An additional and still under-investigated intracellular cancer target is the peroxisome proliferator activated receptor gamma (PPAR-γ). Several studies have shown the in vitro antitumor activity of PPAR-γ agonists in cancer cells but, if used in monotherapy, they were poorly effective in cancer treatment. The present review will focus on the potential therapeutic role of PPAR-γ agonists in combination with other drugs (type I interferons, gemcitabine and COX-2 inhibitors), highlighting molecular interactions and signalling pathways involved in pancreatic cancer cells. Understanding of the underlying molecular mechanisms and survival pathways activated in cancer cells should promote the development of more successful strategies based on the specific targeting of molecular pathways involved in the resistance to anti-cancer agents.
Keywords: Cancer therapy, COX-2 inhibitors, gemcitabine, interferon-β, pancreatic cancer, PPAR-γ, thiazolodinediones.
Current Cancer Drug Targets
Title:Combined Treatment with PPAR-γ Agonists in Pancreatic Cancer: A Glimmer of Hope for Cancer Therapy?
Volume: 13 Issue: 4
Author(s): Alessandra Dicitore, Michele Caraglia, Annamaria Colao, Silvia Zappavigna, Daniela Mari, Leo J. Hofland, Luca Persani and Giovanni Vitale
Affiliation:
Keywords: Cancer therapy, COX-2 inhibitors, gemcitabine, interferon-β, pancreatic cancer, PPAR-γ, thiazolodinediones.
Abstract: Pancreas cancer is the fourth leading cause of cancer death due to the limited treatment success rate. The wide number of signalling pathway aberrations contributing to tumorigenesis, progression and drug resistance, is the main reason for unsuccessful treatments in pancreatic cancer. An additional and still under-investigated intracellular cancer target is the peroxisome proliferator activated receptor gamma (PPAR-γ). Several studies have shown the in vitro antitumor activity of PPAR-γ agonists in cancer cells but, if used in monotherapy, they were poorly effective in cancer treatment. The present review will focus on the potential therapeutic role of PPAR-γ agonists in combination with other drugs (type I interferons, gemcitabine and COX-2 inhibitors), highlighting molecular interactions and signalling pathways involved in pancreatic cancer cells. Understanding of the underlying molecular mechanisms and survival pathways activated in cancer cells should promote the development of more successful strategies based on the specific targeting of molecular pathways involved in the resistance to anti-cancer agents.
Export Options
About this article
Cite this article as:
Dicitore Alessandra, Caraglia Michele, Colao Annamaria, Zappavigna Silvia, Mari Daniela, Hofland Leo J., Persani Luca and Vitale Giovanni, Combined Treatment with PPAR-γ Agonists in Pancreatic Cancer: A Glimmer of Hope for Cancer Therapy?, Current Cancer Drug Targets 2013; 13 (4) . https://dx.doi.org/10.2174/1568009611313040008
DOI https://dx.doi.org/10.2174/1568009611313040008 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Advances in Synthesis of PAR Ligands as Therapeutic Strategy for Inflammatory Diseases
Mini-Reviews in Medicinal Chemistry Altered Glycosylation of Proteins in Cancer: What Is the Potential for New Anti-Tumour Strategies
Anti-Cancer Agents in Medicinal Chemistry Computational and Synthetic Biology Approaches for the Biosynthesis of Antiviral and Anticancer Terpenoids from <i>Bacillus subtilis</i>
Medicinal Chemistry IP6 in Cancer Therapy: Past, Present and Future
Current Cancer Therapy Reviews Short-Chain Fatty Acid Inhibitors of Histone Deacetylases: Promising Anticancer Therapeutics?
Current Cancer Drug Targets Development of Anticancer Agents from Plant-Derived Sesquiterpene Lactones
Current Medicinal Chemistry A Common Biological Mechanism in Cancer and Alzheimers Disease?
Current Alzheimer Research “Dipeptoids”: From the Chemical Structure of the Endogenous Peptide to the Design of Peptidomimetics
Mini-Reviews in Medicinal Chemistry Connection between JAK/STAT and PPARγ Signaling During the Progression of Multiple Sclerosis: Insights into the Modulation of T-Cells and Immune Responses in the Brain
Current Molecular Pharmacology Pancreatic β-Cells and Type 2 Diabetes Development
Current Diabetes Reviews TRPV1: On the Road to Pain Relief
Current Molecular Pharmacology Amino Acid Derived Prodrugs: An Approach to Improve the Bioavailability of Clinically Approved Drugs
Current Topics in Medicinal Chemistry Endothelin Receptor Antagonists: A New Therapeutic Option for Improving the Outcome after Solid Organ Transplantation?
Current Vascular Pharmacology (Neuro)Transmitter Systems in Circulating Immune Cells: A Target of Immunopharmacological Interventions?
Current Medicinal Chemistry The Disposal of Reactive Carbonyl Species through Carnosine Conjugation: What We Know Now
Current Medicinal Chemistry Editorial (Thematic Issue: Myokines and Exercise Training: More Shadows than Lights)
Current Pharmaceutical Design Immunotherapy for Prostate Cancer
Current Pharmaceutical Design Peptide Targeted Copper-64 Radiopharmaceuticals
Current Topics in Medicinal Chemistry The Role of Vitamin D and Sunlight Incidence in Cancer
Anti-Cancer Agents in Medicinal Chemistry Novel Inhibitors of HIV Discovered Among Existing Classes of Pharmaceutical Compounds Indicated for Unrelated Clinical Indications
Current Pharmaceutical Design